Streetbeat News

Products Services

CINT

CI&T (NYSE:CINT) has achieved AWS Well-Architected Authorized Partner status, highlighting its expertise in designing and managing secure applications using AWS best practices. This status differentiates CI&T as an AWS Advanced Consulting Partner with specialized proficiency.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:40 pm

BMY

PRME

Prime Medicine Inc. has entered a strategic collaboration with Bristol Myers Squibb to develop next-generation ex vivo T-cell therapies, potentially worth over $3.5 billion. Prime Medicine will receive $110 million upfront and focus on developing treatments for chronic granulomatous disease and other conditions.

Portfolio Pulse from Vandana Singh

September 30, 2024 | 12:38 pm

ONDS

Ondas Holdings' subsidiary, Airobotics, has secured a $5.4 million purchase order from a major defense customer for its Optimus System, contributing to a total of $14.4 million in purchase orders for Q3 2024. This order highlights the growing adoption of Ondas' autonomous drone platforms in the defense sector.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:37 pm

QUBT

Quantum Computing Inc. has extended its collaboration with Los Alamos National Laboratory to enhance the quantum optimization capabilities of its Dirac-3 platform. This partnership aims to tackle complex problems in energy, telecommunications, and signal processing.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:36 pm

AON

GS

The Milken Institute's Asia Summit and TOKEN2049 in Singapore highlighted the importance of diversifying investments into Asia, particularly China, due to potential growth opportunities. Experts discussed the disruption in global trade, the need for diverse recruitment strategies, and the evolving crypto landscape. AON PLC and Goldman Sachs were mentioned in the context of recruitment and investment strategies.

Portfolio Pulse from Renato Capelj

September 30, 2024 | 12:35 pm

KZR

Kezar Life Sciences has voluntarily stopped enrollment and dosing in its Phase 2b PALIZADE trial of Zetomipzomib for active lupus nephritis patients. This decision could impact the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:35 pm

MBOT

Microbot Medical has accelerated the enrollment rate in its ACCESS-PVI trial, with 80% of patients having completed the follow-up period. The company is on track for an FDA 510(k) submission by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:35 pm

ANIX

Anixa Biosciences has submitted an amendment to its CAR-T trial protocol, allowing a second dose of CAR-T therapy for suitable patients. This development could enhance treatment efficacy and patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:33 pm

NBIX

Neurocrine Biosciences presented interim data showing significant and sustained improvements in chorea associated with Huntington's Disease through week 104, regardless of antipsychotic use.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:33 pm